Epilepsy Trial, Recruiting NCT06557720 Sponsor: Xijing Hospital Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT06557720
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with drug-resistant epilepsy according to the 2010 International League Against Epilepsy (ILAE) criteria
  • People who have had epilepsy for at least 2 years, with seizures happening at least twice per month on average in the 3 months before enrolling
  • People who have tried two or more anti-epilepsy medications at adequate doses, and whose treatment plan will remain unchanged during the trial
  • People who are able to cooperate with the treatment and complete all required examinations, and who (along with their family) have fully understood and signed a consent form

Who may not be able to join:

  • People who are currently experiencing continuous, non-stopping seizures
  • People who have serious infections, cerebrovascular disease, cancer, or severe problems with the heart, liver, kidneys, or other major organs
  • People who have mental health disorders, uncontrolled high blood sugar that cannot be corrected, or who are taking corticosteroid medications long-term
  • People who are pregnant or breastfeeding
  • People for whom PET scans, MRI scans, or EEG tests are not safe or suitable
  • People who have ferromagnetic (certain types of) metal implants in their body, or who currently have a high fever (confirm with trial site)
  • People who are already participating in another clinical trial at the same time
  • People whose consent has been withdrawn by themselves or their family

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jiang Wen, Xi Jing hospital

Phone: 18392320919

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xijing Hospital
Registry
ClinicalTrials.gov
Start date
11 June 2024
Est. completion
11 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The characteristics of hybrid imaging in patients with different types of refractory epilepsy.; The characteristics of PET, fMRI, and EEG indicators in patients with different types of intractable epilepsy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov